DelveInsight’s “ESR1-Mutated Metastatic Breast Cancer Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the ESR1-Mutated Metastatic Breast Cancer, historical and forecasted epidemiology as well as the ESR1-Mutated Metastatic Breast Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The ESR1-Mutated Metastatic Breast Cancer market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
To Know in detail about the ESR1-Mutated Metastatic Breast Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; ESR1-Mutated Metastatic Breast Cancer Market Insights
ESR1-Mutated Metastatic Breast Cancer Overview
Breast cancer occurs when cells in the breast grow out of control and form a growth or tumor.
Tumors may be cancerous (malignant) or not cancerous (benign). A small percentage of all breast cancers cluster in families. These cancers are described as hereditary and are associated with inherited gene mutations. Mutations in the estrogen receptor gene (ESR1) are acquired frequently in metastatic hormone receptor–positive breast cancer.
Some of the key facts of the ESR1-Mutated Metastatic Breast Cancer Market Report:
- The ESR1-Mutated Metastatic Breast Cancer market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
- Mutations affecting the ESR1 gene have been detected mainly in metastases from ER-positive/HER2-negative breast tumors, at a frequency ranging from 5 to 25%, when considering series with >20 interrogated metastases
- ER is expressed in over 60% of breast cancers and consists of two activation function domains, AF1/2, a DNA binding domain and a hinge domain, and a ligand-binding domain (LBD).
- According to the World Health Organization, breast cancer results in more than one million new cases worldwide. About 70% of diagnosed cases express estrogen receptor alpha (ER), where ER signaling is the defining and driving event contributing to tumor growth and disease progression in these ER+ breast tumors
- According to SEER, 63% of the breast cancer are localized (confined to primary site), 29% of the breast cancer cases are regional (spread to regional lymph nodes), 6% of the breast cancer cases are distant (cancer has metastasized) and 2% of the breast cancer cases are unstaged
- Key ESR1-Mutated Metastatic Breast Cancer Companies: Roche, Sermonix Pharmaceutical, Sanofi, and others
- Key ESR1-Mutated Metastatic Breast Cancer Therapies: Giredestrant, Lasofoxifene, SAR439859, and others
Get a Free sample for the ESR1-Mutated Metastatic Breast Cancer Market Report -
https://www.delveinsight.com/sample-request/esr1-mutated-metastatic-breast-cancer-market
Key benefits of the ESR1-Mutated Metastatic Breast Cancer Market report:
- ESR1-Mutated Metastatic Breast Cancer market report covers a descriptive overview and comprehensive insight of the ESR1-Mutated Metastatic Breast Cancer Epidemiology and ESR1-Mutated Metastatic Breast Cancer market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
- The ESR1-Mutated Metastatic Breast Cancer market report provides insights on the current and emerging therapies.
- ESR1-Mutated Metastatic Breast Cancer market report provides a global historical and forecasted market covering drug outreach in 7MM.
- The ESR1-Mutated Metastatic Breast Cancer market report offers an edge that will help develop business strategies by understanding trends shaping and driving the ESR1-Mutated Metastatic Breast Cancer market.
Download the report to understand which factors are driving ESR1-Mutated Metastatic Breast Cancer epidemiology trends @ ESR1-Mutated Metastatic Breast Cancer Epidemiological Insights
ESR1-Mutated Metastatic Breast Cancer Market
The dynamics of the ESR1-Mutated Metastatic Breast Cancer market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.
ESR1-Mutated Metastatic Breast Cancer Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
ESR1-Mutated Metastatic Breast Cancer Epidemiology Segmentation:
The ESR1-Mutated Metastatic Breast Cancer market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalence of ESR1-Mutated Metastatic Breast Cancer
- Prevalent Cases of ESR1-Mutated Metastatic Breast Cancer by severity
- Gender-specific Prevalence of ESR1-Mutated Metastatic Breast Cancer
- Diagnosed Cases of Episodic and Chronic ESR1-Mutated Metastatic Breast Cancer
ESR1-Mutated Metastatic Breast Cancer Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the ESR1-Mutated Metastatic Breast Cancer market or expected to get launched during the study period. The analysis covers ESR1-Mutated Metastatic Breast Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the ESR1-Mutated Metastatic Breast Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Discover more about therapies set to grab major ESR1-Mutated Metastatic Breast Cancer market share @ ESR1-Mutated Metastatic Breast Cancer market forecast
ESR1-Mutated Metastatic Breast Cancer Therapies and Key Companies
- Giredestrant: Roche
- Lasofoxifene: Sermonix Pharmaceutical
- SAR439859: Sanofi
ESR1-Mutated Metastatic Breast Cancer Market Drivers
- Increased incidence of ESR1-mutations in breast cancer in the 7MM
- Increasing demand of novel drugs for ESR1 mutation treatment
Scope of the ESR1-Mutated Metastatic Breast Cancer Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key ESR1-Mutated Metastatic Breast Cancer Companies: Roche, Sermonix Pharmaceutical, Sanofi, and others
- Key ESR1-Mutated Metastatic Breast Cancer Therapies: Giredestrant, Lasofoxifene, SAR439859, and others
- ESR1-Mutated Metastatic Breast Cancer Therapeutic Assessment: ESR1-Mutated Metastatic Breast Cancer current marketed and ESR1-Mutated Metastatic Breast Cancer emerging therapies
- ESR1-Mutated Metastatic Breast Cancer Market Dynamics: ESR1-Mutated Metastatic Breast Cancer market drivers and ESR1-Mutated Metastatic Breast Cancer market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- ESR1-Mutated Metastatic Breast Cancer Unmet Needs, KOL’s views, Analyst’s views, ESR1-Mutated Metastatic Breast Cancer Market Access and Reimbursement
ESR1-Mutated Metastatic Breast Cancer Market Barriers
- Challenges in the identification of ESR1 mutations in standard clinical practice
- There is a paucity of ER-positive PDX models from MBC patients, especially patients with ESR1 mutations.
Table of Contents
1. ESR1-Mutated Metastatic Breast Cancer Market Report Introduction
2. Executive Summary for ESR1-Mutated Metastatic Breast Cancer
3. SWOT analysis of ESR1-Mutated Metastatic Breast Cancer
4. ESR1-Mutated Metastatic Breast Cancer Patient Share (%) Overview at a Glance
5. ESR1-Mutated Metastatic Breast Cancer Market Overview at a Glance
6. ESR1-Mutated Metastatic Breast Cancer Disease Background and Overview
7. ESR1-Mutated Metastatic Breast Cancer Epidemiology and Patient Population
8. Country-Specific Patient Population of ESR1-Mutated Metastatic Breast Cancer
9. ESR1-Mutated Metastatic Breast Cancer Current Treatment and Medical Practices
10. ESR1-Mutated Metastatic Breast Cancer Unmet Needs
11. ESR1-Mutated Metastatic Breast Cancer Emerging Therapies
12. ESR1-Mutated Metastatic Breast Cancer Market Outlook
13. Country-Wise ESR1-Mutated Metastatic Breast Cancer Market Analysis (2019–2032)
14. ESR1-Mutated Metastatic Breast Cancer Market Access and Reimbursement of Therapies
15. ESR1-Mutated Metastatic Breast Cancer Market Drivers
16. ESR1-Mutated Metastatic Breast Cancer Market Barriers
17. ESR1-Mutated Metastatic Breast Cancer Appendix
18. ESR1-Mutated Metastatic Breast Cancer Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
To know more about ESR1-Mutated Metastatic Breast Cancer treatment, visit @ ESR1-Mutated Metastatic Breast Cancer Medications
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
